Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension
Public ClinicalTrials.gov record NCT02960204. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, randomized, double-blind, placebo-controlled trial involving subjects with NASH cirrhosis and severe portal hypertension (defined as HVPG ≥12 mmHg as determined by the central reader assigned to this study). Upon successful screening, subjects will be randomized to receive either emricasan 50 mg BID, 25 mg BID, or 5 mg BID or matching placebo BID.
Study identification
- NCT ID
- NCT02960204
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 263 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 17, 2016 (Actual)
- Primary completion
- Oct 2, 2018 (Actual)
- Completion
- Apr 8, 2019 (Actual)
- Last update posted
- Feb 11, 2022
2016 – 2019
United States locations
- U.S. sites
- 22
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pasadena | Pasadena | California | 91105 | — |
| Rialto | Rialto | California | 92377 | — |
| Palmetto Bay | Palmetto Bay | Florida | 33157 | — |
| Atlanta | Atlanta | Georgia | 30309 | — |
| Clive | Clive | Iowa | 50325 | — |
| Baltimore | Baltimore | Maryland | 21202 | — |
| Detroit | Detroit | Michigan | 48202 | — |
| Rochester | Rochester | Minnesota | 55905 | — |
| Saint Paul | Saint Paul | Minnesota | 55114 | — |
| Kansas City | Kansas City | Missouri | 64131 | — |
| Durham | Durham | North Carolina | 27710 | — |
| Philadelphia | Philadelphia | Pennsylvania | 19104 | — |
| Philadelphia | Philadelphia | Pennsylvania | 19141 | — |
| Germantown | Germantown | Tennessee | 38138 | — |
| Arlington | Arlington | Texas | 76012 | — |
| Houston | Houston | Texas | 77030 | — |
| San Antonio | San Antonio | Texas | 78215 | — |
| San Antonio | San Antonio | Texas | 78233 | — |
| Norfolk | Norfolk | Virginia | 23502 | — |
| Richmond | Richmond | Virginia | 23226 | — |
| Richmond | Richmond | Virginia | 23249 | — |
| Seattle, Washington | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02960204, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 11, 2022 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02960204 live on ClinicalTrials.gov.